SEC Form SC 13G filed by AN2 Therapeutics Inc.

$ANTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ANTX alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $ANTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANTX

DatePrice TargetRatingAnalyst
8/9/2024In-line → Underperform
Evercore ISI
8/9/2024$5.00 → $1.00Outperform → Market Perform
Leerink Partners
7/3/2024$5.00Market Perform → Outperform
Leerink Partners
4/2/2024$6.00Mkt Perform → Mkt Outperform
JMP Securities
2/13/2024$23.00 → $7.00Outperform → Market Perform
Leerink Partners
2/12/2024$25.00 → $7.00Outperform → In-line
Evercore ISI
2/12/2024Outperform → Perform
Oppenheimer
2/12/2024Mkt Outperform → Mkt Perform
JMP Securities
More analyst ratings

$ANTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

    Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first in human study of AN2-502998, under development for Chagas disease, to start mid-2025 in healthy volunteers Topline data for melioidosis observational trial expected in 2Q25; Phase 2 epetraborole study planned for 2H25 First oncology candidate(s) from boron chemistry platform on track to advance into development in 2H25 Cash, cash equivalents, and investments of $88.6 million at December 31, 2024 anticipated to fund operations through 2027 under current strategic plan AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering an

    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, March 12, 2025 at 2:20 pm ET, and members of management will be available for 1X1 meetings. A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutic

    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

    AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome (PRO) instrument as the primary efficacy endpoint for the Phase 3 part of the EBO-301 trial. The Company will evaluate whether the Phase 3 data supports the Phase 2 findings, where potentia

    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANTX
SEC Filings

See more

$ANTX
Leadership Updates

Live Leadership Updates

See more
  • Brii Biosciences Provides Latest Clinical Development and Corporate Updates

    Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

    AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a

    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANTX
Financials

Live finance-specific insights

See more
  • AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all

    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

    Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi

    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

    Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$ANTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more